[Perspectives of scintigraphic diagnosis of malignant lymphoma using a new radiopharmaceutical].
In the sequence of our studies on radiopharmaceuticals for malignant melanoma detection the results were most promising for the possible use of 125I or 123I-N-(2-diethyl amino ethyl)4-iodobenzamide. The biodistribution in mice bearing melanoma either human or animal from 4 to 24 hrs. post i.v. injection showed high uptake in tumor tissue together with relatively low uptake in muscle, brain, lung and liver. Scintigraphic images of the tumor obtained at the same times confirmed that melanoma detection was very promising.
Meyniel
G
G
Unité I.N.S.E.R.M. 71, Clermont-Ferrand.
Michelot
J
J
Moreau
M F
MF
Veyre
A
A
D000818:Animals; D001549:Benzamides / Q000493:pharmacokinetics; D003287:Contrast Media; D008545:Melanoma / Q000000981:diagnostic imaging*; D008722:Methods; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D011877:Radionuclide Imaging
D001549:Benzamides; D003287:Contrast Media; C066918:N-(2-(diethylamino)ethyl)-4-iodobenzamide
Perspectives de diagnostic scintigraphique du mélanome malin par un nouveau radiopharmaceutique.